GlyNAC (Glycine + N-Acetylcysteine)
GlyNAC (Glycine + N-Acetylcysteine) scored 6.7 / 10 (👍 Worth trying) on the BioHarmony scale as a Substance → Amino Acid.
GlyNAC is glycine plus N-acetylcysteine, a precursor stack that rebuilds the body's master antioxidant glutathione. In a 16-week randomized trial of older adults, Kumar 2023 reported insulin resistance fell 64 percent and muscle glutathione rose 164 percent. The effects are large but concentrated in one small-trial research program.
What is GlyNAC (Glycine + N-Acetylcysteine)?
GlyNAC is a two-ingredient supplement stack that combines glycine and N-acetylcysteine, and its whole job is to help your body rebuild glutathione, the master antioxidant that every cell uses to control oxidative stress. It scores 6.7 out of 10, a worth-trying rating that reflects an honest split: the human effect sizes are unusually large and the safety is excellent, but almost all the dramatic data comes from a single research program in small groups. The logic is that glutathione synthesis falls with age, and the two amino acids that limit how fast cells can make it are cysteine, supplied here as N-acetylcysteine, and glycine. Give the body both and it makes its own glutathione far more effectively than swallowing glutathione directly.
The reason GlyNAC earns a strong-but-measured score rather than a glowing one is concentration of evidence. The Sekhar group at Baylor has run a series of trials showing GlyNAC lowers insulin resistance, improves mitochondrial function, and boosts strength and cognition in older adults, with effect sizes most supplements never approach. But these are trials of 8 to 24 people, and the one larger independent trial did not reproduce the headline glutathione rise. GlyNAC is the precursor route to the same target as the glutathione report, and on bioavailability it clearly wins; what it still needs is independent replication of the outcomes.
Terminology
GlyNAC sits at the intersection of amino-acid biochemistry and aging research, and a few terms decide how you read the evidence. The most important distinction is between the precursors and the product: GlyNAC supplies building blocks, while glutathione is what the body makes from them. Knowing that the strongest data comes from one laboratory, and that effects fade when you stop, changes how confidently you should read the headline numbers. The terms below appear throughout this report.
- GlyNAC: The combination of glycine plus N-acetylcysteine, taken together to rebuild glutathione.
- NAC: N-acetylcysteine, a cysteine-supplying precursor and the standard antidote for acetaminophen overdose.
- Glycine: A small dietary amino acid and the second rate-limiting precursor for glutathione synthesis.
- GSH: Glutathione in its active reduced form, the working master antioxidant.
- Glutathione synthesis: The cellular process of building glutathione from cysteine, glycine, and glutamate, which slows with age.
- HOMA-IR: Homeostatic model assessment of insulin resistance, a blood-based measure of how resistant the body is to insulin.
- Mitochondrial fatty-acid oxidation: How efficiently mitochondria burn fat for energy, which improves when glutathione is restored.
- Oxidative stress: An imbalance where reactive oxygen species outpace antioxidant defenses and damage cells.
- TBARS: Thiobarbituric acid reactive substances, a marker of lipid-peroxidation oxidative damage.
- F2-isoprostane: A reliable blood and urine marker of oxidative stress from lipid peroxidation.
- Aging hallmarks: A set of cellular defects, such as mitochondrial dysfunction and cellular senescence, that drive biological aging.
- Washout: A study phase where supplementation stops to see whether benefits persist or fade.
How do you take GlyNAC (Glycine + N-Acetylcysteine)?
Dosing & Protocols
Dosing information is summarized from published research and community reports. This is not a prescribing guide. Consult a healthcare provider before starting any protocol.
Routes & Forms
| Route | Form | Clinical Range | Community Range |
|---|---|---|---|
| Oral powder (glycine plus NAC) | Loose powder, dosed by body weight | About 100 mg/kg/day each of glycine and NAC | 3 to 10 g glycine plus 0.6 to 2.4 g NAC per day |
| Oral capsule (fixed-dose blend) | Capsules or tablets, often a branded GlyNAC blend | Below trial dose; varies by product | 1 to 3 g glycine plus 600 to 1,200 mg NAC per day |
Protocols
Trial-mirroring older-adult protocol Clinical
- Dose
- Glycine and NAC at ~100 mg/kg/day each
- Frequency
- Daily, split into 2 to 3 servings
- Duration
- 16 to 24 weeks, then reassess
Mirrors Kumar 2023 and the 2021 pilot. Pair with a baseline and follow-up marker because the benefit is gradual and fades on stopping.
Modest maintenance stack Mixed
- Dose
- Glycine 3 g plus NAC 600 to 1,200 mg
- Frequency
- Daily
- Duration
- Ongoing
A lower, more tolerable dose for general antioxidant and sleep support from glycine plus the glutathione-precursor benefit of NAC. Expect smaller effects than the full trial dose.
How this score is calculated →
What are the benefits of GlyNAC (Glycine + N-Acetylcysteine)?
Upside contribution: 2.10
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Efficacy | 25% | 3.4 | 0.850 | |
| Breadth | 15% | 3.6 | 0.540 | |
| Evidence | 25% | 2.8 | 0.700 | |
| Speed | 10% | 3.0 | 0.300 | |
| Durability | 10% | 2.0 | 0.200 | |
| Bioindividuality | 15% | 3.4 | 0.510 | |
| Total | 3.100 |
Upside Rationale
The upside of GlyNAC comes from large, functionally meaningful human effects built on a sound precursor mechanism, tempered by how few labs have produced them. The strongest support comes from Kumar 2023, a 16-week double-blind RCT in older adults showing not just biomarker shifts but real-world gains in strength, gait, and insulin sensitivity. The boundary condition is everything: the magnitude is striking, the population is older and glutathione-depleted, and the data is concentrated in one program of small trials. This is a molecule pair whose biology is solid and whose human payoff is genuinely large where it has been measured.
Efficacy (3.4/5.0): Real-world clinical magnitude is the standout, which is why efficacy sits well above the midpoint despite thin replication. Kumar 2023 reported insulin resistance fell 64 percent and functional measures of strength and gait improved significantly over 16 weeks in older adults, while the diabetes pilot Sekhar 2022 lowered insulin resistance 22 percent in just 14 days. These are clinical and functional endpoints, not only surrogate markers, which is exactly what the rubric rewards. The honest discount is that the larger independent Lizzo 2022 trial did not reproduce the central glutathione rise, so the true population effect may be smaller than the single-lab figures suggest.
Breadth of Benefits (3.6/5.0): The mechanism reaches an unusually wide set of systems with at least one human endpoint each. Kumar 2023 reported gains across metabolism (HOMA-IR), mitochondria (fatty-acid oxidation up 78 percent), inflammation (IL-6 down 78 percent), muscle function (grip and chair-rise), cardiovascular markers (lower systolic blood pressure), and body composition (reduced waist circumference), plus improvement in several aging hallmarks. Few interventions touch this many real endpoints in one trial. The scope boundary is that the breadth is demonstrated mainly in older, depleted populations and from one research group, so it reads as broad and real but not yet broadly confirmed.
Evidence Quality (2.8/5.0): Evidence is the limiting dimension. There are genuine randomized, placebo-controlled human trials, which is more than many supplements can claim, plus a foundational stable-isotope study and aging-mouse data. But the trials are small, 8 to 24 participants, and almost all of them come from the Sekhar group at Baylor, which is a concentration problem rather than an RCT-absence problem. The decisive counterweight is the larger independent Lizzo 2022 trial (n=114), which missed its primary glutathione endpoint and only found benefit in a high-oxidative-stress subset. This is not a penalty for lacking trials; it is an honest read that the most dramatic outcomes are single-lab and not yet replicated.
Speed of Onset (3.0/5.0): Onset is moderate and endpoint-dependent. Oxidative-stress markers and insulin resistance began improving within 2 weeks in Kumar 2023, and the diabetes pilot saw mitochondrial and insulin changes in 14 days. Functional gains in strength, gait, and cognition built more slowly over 16 to 24 weeks. There is no acute felt effect to chase, so a baseline-and-reassess approach over about 3 months fits how the benefits actually accrue.
Durability (2.0/5.0): Benefits depend on continued dosing, which lowers this dimension. The Kumar 2021 pilot included a 12-week washout, and most improvements, including glutathione, oxidative stress, insulin resistance, strength, and cognition, declined back toward baseline once supplementation stopped. That makes GlyNAC a maintenance protocol: you are continuously replacing precursors the aging body no longer supplies in adequate amounts, rather than making a one-time correction that locks in.
Bioindividuality Upside (3.4/5.0): Response varies in a way that is a genuine upside for the right person. The likeliest strong responders are older adults, people with type 2 diabetes, and anyone with documented glutathione depletion or high oxidative-stress burden, mirroring exactly where Kumar 2023 and Sekhar 2022 found effects. The Lizzo 2022 subset finding reinforces this: benefit clustered in participants with high baseline oxidative stress and low glutathione. Healthy, young, well-nourished users with normal glutathione have little human data and should expect less, which rewards self-tracking against a baseline marker.
What are the risks & downsides of GlyNAC (Glycine + N-Acetylcysteine)?
Downside contribution: 0.71 (safety risks weighted extra)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Safety | 30% | 1.5 | 0.450 | |
| Side effects | 15% | 1.7 | 0.255 | |
| Cost | 5% | 1.8 | 0.090 | |
| Effort | 5% | 1.8 | 0.090 | |
| Opportunity | 5% | 2.2 | 0.110 | |
| Dependency | 15% | 1.2 | 0.180 | |
| Reversibility | 25% | 1.5 | 0.375 | |
| Total | 1.550 | |||
| Harm subtotal × 1.4 | 1.764 | |||
| Opportunity subtotal × 1.0 | 0.290 | |||
| Combined downside | 2.054 | |||
| Baseline offset (constant) | −1.340 | |||
| Effective downside penalty | 0.714 |
Downside Rationale
The downside of GlyNAC is mild and dominated by opportunity cost and uncertainty rather than harm. Both ingredients are cheap, old, and very safe, with no dependency, easy reversibility, and benign side effects at sensible doses. The dominant practical concerns are that the trial dose is large and slightly fiddly, that a simpler NAC-only or precursor approach might do much of the job, and that the dramatic benefits are not yet independently confirmed. Per the intrinsic-baseline rule, this report scores correctly-dosed, correctly-sourced GlyNAC, and there is no intrinsic catastrophic safety signal to invoke a floor.
Safety Risk (1.5/5.0): GlyNAC is benign at sensible doses. N-acetylcysteine has decades of human use as a mucolytic and as the acetaminophen-overdose antidote validated by Prescott 1977, and glycine is a common dietary amino acid generally recognized as safe. The GlyNAC trials reported supplementation was well tolerated with no significant adverse events over 16 to 24 weeks. There is no intrinsic life-threatening signal that would trigger the catastrophic floor; rare NAC-related bronchospasm and the usual amino-acid interaction checks are the only real cautions, and they belong in a use-it-sensibly note rather than inflating this dimension.
Side Effect Profile (1.7/5.0): Side effects are minimal and dose-related. The most common reports come from the NAC component: a sulfur taste, mild nausea, or loose stools, especially at the large trial doses, all of which ease with food and lower starting amounts. Glycine is essentially free of nuisance effects and may even improve sleep. There is no consistent pattern of headaches or other adverse effects in the supplement-dose literature, making the side-effect profile a genuine strength.
Financial Cost (1.8/5.0): Cost is low. Bulk glycine and N-acetylcysteine powders are inexpensive, running roughly $10 to $30 per month even at higher doses, which is one of GlyNAC's strongest practical advantages over patented or branded longevity products. Pre-blended branded GlyNAC capsules cost more per gram, but the do-it-yourself powder route keeps the whole protocol cheap.
Time/Effort Burden (1.8/5.0): Effort is modest but not zero. The trial protocol is a large weight-based powder dose split across the day, which takes a little measuring and mixing, and NAC's taste means most people prefer to take it with food. There is no cycling requirement or complex timing, though committing to a multi-month trial with before-and-after markers takes some discipline given the gradual onset.
Opportunity Cost (2.2/5.0): This is the most meaningful downside. NAC alone is cheaper, better established, and does much of the glutathione-precursor work, so part of GlyNAC's benefit is available without the glycine and the larger dose. Money and attention could also go to interventions with broader independent confirmation. GlyNAC is not a wasted slot, especially for older or metabolically impaired users, but for a healthy person it may not be the highest-leverage choice until the outcomes replicate more widely.
Dependency/Withdrawal (1.2/5.0): There is no dependency or withdrawal. Both amino acids are normal dietary components, and stopping simply returns glutathione synthesis to its untreated rate with no craving, rebound, or adaptation syndrome.
Reversibility (1.5/5.0): Reversibility is clean, with one nuance. You can stop at any time with no taper and no lasting harm, but the benefits also fade, declining back toward baseline within about 12 weeks per the Kumar 2021 washout. That is easy discontinuation, but it also means the gains are rented, not owned.
Is GlyNAC (Glycine + N-Acetylcysteine) worth it?
GlyNAC is a 6.7 out of 10, worth trying and arguably the best-evidenced way to raise glutathione, while still carrying an honest asterisk about replication. The practical verdict is to treat it as a low-cost, high-safety experiment that is most likely to pay off in older adults, people with type 2 diabetes, or anyone with measured glutathione depletion. The effect sizes in the human trials, a 64 percent drop in insulin resistance and large gains in strength and mitochondrial function, are far beyond what most supplements deliver, and the precursor approach cleanly beats swallowing glutathione directly. The reason it lands in worth-trying rather than strong-recommend is that nearly all of that data comes from one laboratory in groups of a dozen people, and the single larger independent trial missed its primary endpoint. The score tier is justified by excellent safety and large demonstrated effects pulling up against concentrated, not-yet-replicated evidence and washout-dependent durability pulling down.
✅ Best for: Older adults, especially those over 65, who are the studied population and the most likely to be glutathione-depleted; people with type 2 diabetes or insulin resistance who will track HbA1c or HOMA-IR, the metabolic markers with the strongest signal; anyone with documented high oxidative-stress burden, the subset that benefited even in the independent Lizzo 2022 trial; biohackers who want the precursor route to glutathione rather than the poorly-absorbed direct form; and budget-conscious experimenters who value a cheap, very safe protocol they can run on themselves with a marker in hand.
❌ Avoid if: You expect a dramatic acute effect, because GlyNAC works gradually over weeks to months; you want a one-and-done fix, since benefits fade within about 12 weeks of stopping; you are a healthy, young, well-nourished person with normal glutathione, where human data is thin and the upside is smaller; you have asthma with a history of NAC-triggered bronchospasm, in which case introduce NAC cautiously and with clinician input; or you would rather wait for larger independent trials to confirm the single-lab outcomes before committing.
What is GlyNAC (Glycine + N-Acetylcysteine) best for?
The overall BioHarmony score reflects the intervention's primary evidence profile. These subratings are independent assessments per use case.
Mitochondrial: 7.0/10
Score: 7.0/10Mitochondrial function is GlyNAC's strongest and most distinctive case, scoring 7.0/10, because the precursor route is mechanistically tied to mitochondrial fuel oxidation and the human data is unusually large. Kumar 2023 reported mitochondrial fatty-acid oxidation improved 78 percent at 16 weeks in older adults, and the type 2 diabetes pilot Sekhar 2022 found a 30 percent improvement in just 14 days. The mechanism is coherent: glutathione adequacy is required for efficient mitochondrial fatty-acid oxidation, and restoring it reverses the defect. The honest cap is that these are small single-lab trials. This is the use case where GlyNAC most clearly outperforms swallowing glutathione directly.
Antioxidant / Oxidative Stress: 6.5/10
Score: 6.5/10Antioxidant support scores 6.5/10 and is the most mechanistically certain benefit, since the entire point of GlyNAC is to rebuild glutathione, the cell's master redox buffer. Kumar 2023 reported red-cell glutathione rose 225 percent and the oxidative markers TBARS and F2-isoprostane each fell 72 percent at 16 weeks, a much larger effect than oral glutathione achieves. The original Sekhar 2011 stable-isotope work showed the precursors fully restored deficient glutathione synthesis in older adults. The reason this is not higher is replication: the larger independent Lizzo 2022 trial did not raise glutathione in its overall cohort, only in a high-oxidative-stress subset.
Blood Sugar / Glycemic Control: 6.5/10
Score: 6.5/10Glycemic control earns 6.5/10 on the back of the single largest effect in the literature. Kumar 2023 reported HOMA-IR insulin resistance fell 64 percent over 16 weeks in older adults, and the type 2 diabetes pilot Sekhar 2022 found a 22 percent drop in insulin resistance in just 14 days alongside improved mitochondrial glucose handling. Glycine itself has independent glycemic-support signals. The effect size is striking and biologically plausible through mitochondrial fuel oxidation, but it is concentrated in small trials from one group, and no large independent diabetes outcome trial has confirmed durable HbA1c benefit, which keeps the score in worth-trying rather than higher.
Longevity / Lifespan: 5.8/10
Score: 5.8/10Longevity scores 5.8/10 because GlyNAC is one of the few supplements with human data on multiple hallmarks of aging, not just a surrogate marker. Kumar 2023 reported improvement in several aging hallmarks including mitochondrial dysfunction, inflammation, genomic damage, cellular senescence, and stem-cell exhaustion in older adults over 16 weeks. Mouse work from the same program reported lifespan extension. The honest discount is large: there is no human lifespan or hard-outcome trial, the hallmark improvements are biomarker-level, and the data is single-lab in groups of a dozen. It is a credible, mechanism-rich longevity bet rather than proven longevity medicine, and the better-replicated version of the bet is the metabolic and functional one.
Geriatric / Aging Population: 6.0/10
Score: 6.0/10Older adults are GlyNAC's home population and the case scores 6.0/10. Glutathione synthesis is documented to fall with age in Sekhar 2011, and correcting it produced functional gains: Kumar 2023 reported significant improvements in gait speed, grip strength, and the chair-rise test in adults aged 65 and older, alongside lower blood pressure and waist circumference. The pilot showed similar strength and cognition gains. These are real-world functional endpoints, not just lab values, which is what lifts this use case. The limitation is the same throughout: the trials are small and from one center, so the magnitude may not generalize.
Metabolic Health: 6.0/10
Score: 6.0/10Metabolic health scores 6.0/10, carried by the insulin-resistance and mitochondrial data. Kumar 2023 reported a 64 percent fall in HOMA-IR plus reduced waist circumference, and the diabetes pilot Sekhar 2022 lowered insulin resistance and free fatty acids in 14 days. The metabolic story is coherent because restoring glutathione improves mitochondrial fuel oxidation, which is upstream of insulin sensitivity. The cap reflects trial size and single-lab concentration, and the fact that the larger independent trial did not reproduce the glutathione rise that the whole metabolic mechanism depends on.
Anti-Inflammatory: 5.5/10
Score: 5.5/10Anti-inflammatory effects score 5.5/10. Kumar 2023 reported IL-6 down 78 percent and TNF-alpha down 54 percent at 16 weeks, with the anti-inflammatory cytokine IL-10 nearly doubling, a consistent and sizable shift across multiple markers. The mechanism is credible: restoring glutathione dampens redox-sensitive inflammatory signaling. The reason this is not higher is that the inflammation findings ride on the same small single-lab cohorts and have not been independently replicated, so the marker movement is encouraging but not yet confirmed across groups.
Healthspan: 5.5/10
Score: 5.5/10Healthspan scores 5.5/10 because the functional gains in strength, gait, glycemic control, and inflammation are exactly the kind of compression-of-morbidity signals healthspan is about, per Kumar 2023. The discount is that all of it is single-lab and biomarker-or-function-level rather than hard-outcome, so the healthspan case is promising and mechanism-rich but not independently confirmed.
Energy / Fatigue: 5.0/10
Score: 5.0/10Energy and fatigue score 5.0/10 on indirect but plausible grounds. Improved mitochondrial fuel oxidation and lower oxidative stress are energy-relevant, and older participants reported better physical function, but there is no dedicated fatigue endpoint with a clean placebo comparison. Treat any energy benefit as a personal experiment tracked against a baseline.
Neuroprotection: 5.0/10
Score: 5.0/10Neuroprotection scores 5.0/10. The Kumar 2021 pilot reported cognitive gains on the Montreal Cognitive Assessment and Trail-Making tests in older adults, and glutathione is depleted in several neurodegenerative states. But the cognition data is from a tiny open-label pilot, the gains faded on washout, and no controlled neuroprotection trial exists, so this rests on mechanism plus a small signal.
Cognition / Focus: 5.0/10
Score: 5.0/10Cognition scores 5.0/10 on the strength of the pilot signal. Kumar 2021 reported improved cognitive test scores and verbal fluency in older adults over 24 weeks, declining after stopping. This is a real but small open-label finding without a placebo arm, so it supports a cautious mechanistic case rather than a proven nootropic effect, and healthy younger users should expect little.
Strength / Power: 5.0/10
Score: 5.0/10Strength scores 5.0/10 because Kumar 2023 reported significant grip-strength and chair-rise improvements in older adults, a genuine functional endpoint. The signal is real but limited to small trials in an older, glutathione-depleted population, so it may not transfer to younger or trained users.
| Use Case | Score | Summary |
|---|---|---|
| ○ Recovery / Repair | 4.5 | Recovery support scores 4.5/10 on indirect grounds: lower oxidative stress and better mitochondrial function plus glycine's role in collagen and sleep could aid recovery, but GlyNAC has no dedicated exercise-recovery trial with meaningful endpoints. |
| ○ Cardiovascular | 4.5 | Cardiovascular scores 4.5/10. Kumar 2023 reported lower systolic blood pressure and improved endothelial function in older adults, and the pilot noted reduced endothelial dysfunction, but these are small trials without cardiovascular event endpoints, so the case is real but early. |
| ○ Liver / Detoxification | 4.5 | Liver support scores 4.5/10. The NAC component is the proven antidote that restores hepatic glutathione in acetaminophen overdose, validating the detoxification pathway, but GlyNAC as a combination has no dedicated liver-outcome trial, so the case rests on the precursor mechanism rather than direct evidence. |
| ○ Body Composition / Fat Loss | 4.5 | Body composition scores 4.5/10. Kumar 2023 reported reduced waist circumference and fat mass in older adults, a real signal, but it is secondary to the metabolic effects and unproven as a primary weight-loss tool. |
| ○ Stress / Resilience | 4.0 | Stress resilience scores 4.0/10. Oxidative-stress reduction is mechanistically adjacent to physiological resilience, and glycine supports sleep and calm, but there is no direct human resilience or HPA-axis trial for the combination. |
| ○ Immune Function | 4.0 | Immune support scores 4.0/10 on mechanism plus the broader glutathione literature, since glutathione is essential to lymphocyte function, but GlyNAC itself has no dedicated immune-outcome trial. |
| ○ Sleep Quality | 4.0 | Glycine alone has small trials supporting better subjective sleep quality and faster sleep onset, which carries into the stack, but this is a glycine effect rather than a GlyNAC-specific finding. Scores 4.0/10. |
| ○ Endurance / Cardio | 4.0 | Exercise capacity improved in the older-adult pilot, plausibly through better mitochondrial fuel oxidation, but there is no dedicated endurance trial in trained populations. Scores 4.0/10. |
| ○ Fertility (Male) | 3.5 | Antioxidant support of sperm parameters is plausible through the broader thiol pathway, and NAC has some fertility data, but GlyNAC-specific human fertility evidence is absent. Scores 3.5/10. |
| ○ Mood / Emotional Regulation | 3.5 | NAC has independent psychiatric data and glycine affects NMDA signaling, but the GlyNAC combination has no direct mood trial, so the case is indirect. Scores 3.5/10. |
| ○ Telomere / DNA Repair | 3.5 | Reduced genomic damage was reported as one of the improved aging hallmarks in Kumar 2023, but this is a biomarker-level finding in a small single-lab trial, not a telomere outcome. Scores 3.5/10. |
| ○ Cellular Senescence | 3.5 | Cellular senescence was listed among the improved hallmarks in the older-adult RCT, but it is a mechanistic biomarker finding without independent replication. Scores 3.5/10. |
| ○ Respiratory | 3.5 | NAC alone has a mucolytic and respiratory track record, but GlyNAC as a combination has no respiratory outcome trial, so the credit is for the NAC component only. Scores 3.5/10. |
| ○ Kidney Function | 3.0 | Kidney support is mechanistic only, with antioxidant protection of renal tissue but no GlyNAC-specific human outcome trial. Scores 3.0/10. |
| ○ Stem Cell Support | 3.0 | Stem-cell exhaustion was named as one of the improved aging hallmarks, but this rests on a single small trial and indirect markers. Scores 3.0/10. |
| ○ Autophagy | 3.0 | Mitophagy improvement was reported among the aging hallmarks, but human autophagy endpoints for GlyNAC are minimal. Scores 3.0/10. |
| ○ Heavy Metal / Toxin Burden | 3.0 | Glutathione conjugates some toxins via Phase II enzymes and NAC is used in some metal-chelation contexts, but there is no GlyNAC clinical detox outcome. Scores 3.0/10. |
Frequently Asked Questions
What is GlyNAC and how does it work?
GlyNAC is a combination of two amino acids, glycine and N-acetylcysteine, that together supply the rate-limiting building blocks the body needs to make glutathione, its master intracellular antioxidant. Glutathione synthesis falls with age per Sekhar 2011, and NAC delivers cysteine while glycine fills the second gap. Restoring glutathione lowers oxidative stress and, importantly, improves mitochondrial fuel oxidation, which is upstream of energy production and insulin sensitivity. The combination raises glutathione far more effectively than swallowing glutathione directly does.
Is GlyNAC better than taking glutathione directly?
For raising glutathione, the precursor route usually wins. Oral glutathione is poorly absorbed because gut enzymes break it apart, so a single dose barely moves blood levels. GlyNAC instead supplies well-absorbed amino acids the cell uses to build its own glutathione: Kumar 2023 reported red-cell glutathione rose 225 percent, a much larger gain than oral glutathione trials achieve. GlyNAC also adds glycine, which oral glutathione does not. The tradeoff is dose size and the fact that GlyNAC's strongest data comes from one small-trial research program.
How much GlyNAC should I take and when?
The trials used a large weight-based dose: about 100 mg/kg/day each of glycine and N-acetylcysteine, which is roughly 7 grams of each for a 70 kg adult, split across the day. Many people use smaller fixed doses such as 3 grams of glycine with 600 to 1,200 mg of NAC, which is more tolerable but likely milder. Take it with food to ease NAC's sulfur taste and any stomach upset. Because effects build over weeks and fade on stopping, commit to a 16 to 24 week trial with a tracked marker.
What does the human evidence on GlyNAC actually show?
The headline data is striking but concentrated. Kumar 2023, a 16-week randomized placebo-controlled trial in 24 older adults, reported insulin resistance down 64 percent, muscle glutathione up 164 percent, lower inflammation, and gains in strength and gait. A 24-week pilot and a diabetes pilot pointed the same way. The honest caveat: nearly all of this comes from one laboratory, the Sekhar group at Baylor, in groups of 8 to 24 people, and the larger independent Lizzo 2022 trial (n=114) missed its primary glutathione endpoint.
Is GlyNAC safe to take long term?
GlyNAC has a reassuring safety profile because both ingredients are old, cheap, and well studied. N-acetylcysteine has decades of use as a mucolytic and the acetaminophen-overdose antidote, and glycine is a common dietary amino acid generally recognized as safe. In the GlyNAC trials, supplementation was well tolerated with no significant adverse events. The main practical issues are mild and dose-related: NAC can cause a sulfur taste, nausea, or loose stools at high doses, and rare bronchospasm has been reported. Taking it with food and starting lower reduces these.
Who benefits most from GlyNAC?
The clearest responders are older adults and people with type 2 diabetes, the groups studied in the trials and the populations most likely to be glutathione-depleted. Kumar 2023 found functional gains specifically in adults aged 65 and up, and the diabetes pilot Sekhar 2022 improved insulin resistance in patients with diabetes. Healthy younger people with normal glutathione have little human data and may notice less. The best candidate is someone with measured depletion or a metabolic marker to track, willing to run a multi-month trial.
How fast does GlyNAC work?
Different effects move on different timelines. Oxidative-stress markers and insulin resistance began improving within 2 weeks in Kumar 2023, while functional gains in strength, gait, and cognition built over 16 to 24 weeks. Because the meaningful changes are gradual, set a baseline marker such as HbA1c or grip strength and reassess after about 3 months rather than chasing an immediate sensation. The benefits also fade within roughly 12 weeks of stopping, so it works only while you keep taking it.
Do the benefits of GlyNAC last after you stop?
No, the benefits largely reverse. In the Kumar 2021 pilot, stopping GlyNAC for 12 weeks led most improvements, including glutathione levels, oxidative stress, insulin resistance, strength, and cognition, to decline back toward baseline. That makes GlyNAC a maintenance protocol rather than a one-time correction: you are continuously supplying precursors the aging body no longer makes enough of. There is no withdrawal syndrome or rebound worse than baseline; the effect simply fades as glutathione synthesis returns to its untreated rate.
Can I just take NAC instead of GlyNAC?
You can take NAC alone, but the trials deliberately added glycine because both amino acids are rate-limiting for glutathione synthesis in older adults. The Sekhar program's argument, grounded in Sekhar 2011, is that supplying cysteine through NAC plus glycine corrects the deficiency more completely than either alone. Glycine also contributes independent benefits for sleep and metabolic health. NAC alone is a reasonable cheaper option and is the better-established ingredient, but the combination is what the human aging data actually tested.
What could change GlyNAC (Glycine + N-Acetylcysteine)'s score?
BioHarmony scores are living assessments. New research, regulatory changes, or personal context can shift the score up or down. These are the most likely scenarios that would change this intervention's rating.
The most plausible update that would move this score is a large, independent, placebo-controlled outcome trial of GlyNAC in older or metabolically impaired adults. A clear positive replication of the insulin-resistance and functional gains would lift efficacy and evidence together and push GlyNAC into the strong-recommend tier; another null independent trial like Lizzo 2022 would pull evidence and efficacy down toward neutral. The dimensions most likely to move first are evidence and efficacy, since safety, dependency, and reversibility are already near their floors and unlikely to change.
| Scenario | Dimension shifts | New Score |
|---|---|---|
| A large independent RCT replicates the insulin-resistance and functional gains | Efficacy 3.4 to 4.2, evidence 2.8 to 4.0 | 7.4 / 10 💪 Strong recommend |
| A second independent group confirms the mitochondrial and metabolic effects | Evidence 2.8 to 3.8, breadth 3.6 to 4.1 | 7.1 / 10 💪 Strong recommend |
| A long-term trial shows benefits persist with continued dosing and hard outcomes | Durability 2.0 to 3.0, efficacy 3.4 to 4.0 | 7.0 / 10 💪 Strong recommend |
| Further independent trials come back null like the Lizzo 2022 result | Efficacy 3.4 to 2.8, evidence 2.8 to 2.2 | 6.4 / 10 👍 Worth trying |
| A specific intrinsic safety signal emerges at trial doses | Safety 1.5 to 3.0, side effects 1.7 to 2.8 | 5.7 / 10 ⚖️ Neutral |
| NAC-only proves to match GlyNAC, collapsing the combination rationale | Efficacy 3.4 to 2.2, evidence 2.8 to 2.0, opportunity 2.2 to 3.0 | 6.1 / 10 👍 Worth trying |
Key Evidence Sources
- Sekhar RV et al. 2011 - Deficient synthesis of glutathione underlies oxidative stress in aging and can be corrected by dietary cysteine and glycine supplementation, American Journal of Clinical Nutrition. Stable-isotope study, n=16: older adults had deficient red-cell glutathione synthesis; 2 weeks of cysteine plus glycine fully restored synthesis and concentrations and lowered oxidative stress. Foundational precursor rationale.
- Kumar P et al. 2021 - Glycine and N-acetylcysteine (GlyNAC) supplementation in older adults improves glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, insulin resistance, endothelial dysfunction, genotoxicity, muscle strength, and cognition, Clinical and Translational Medicine. Open-label pilot, n=8 older adults, 24 weeks plus 12-week washout: broad improvements across glutathione, oxidative stress, strength, gait, and cognition that declined after stopping. Single-lab, no placebo.
- Kumar P et al. 2023 - Supplementing Glycine and N-Acetylcysteine (GlyNAC) in Older Adults Improves Glutathione Deficiency, Oxidative Stress, Mitochondrial Dysfunction, Inflammation, Physical Function, and Aging Hallmarks: A Randomized Clinical Trial, The Journals of Gerontology: Series A. Double-blind RCT, n=24 older adults, 16 weeks vs alanine placebo: HOMA-IR down 64 percent, muscle glutathione up 164 percent, IL-6 down 78 percent, plus gains in gait, grip, and chair-rise. The flagship trial, but small and single-lab.
- Sekhar RV 2022 - GlyNAC (Glycine and N-Acetylcysteine) Supplementation Improves Impaired Mitochondrial Fuel Oxidation and Lowers Insulin Resistance in Patients with Type 2 Diabetes: Results of a Pilot Study, Antioxidants. Pilot, 10 type 2 diabetes patients vs 10 controls, 14 days: mitochondrial fatty-acid oxidation improved 30 percent, insulin resistance down 22 percent, free fatty acids down 25 percent. Small and short.
- Lizzo G et al. 2022 - A Randomized Controlled Clinical Trial in Healthy Older Adults to Determine Efficacy of Glycine and N-Acetylcysteine Supplementation on Glutathione Redox Status and Oxidative Damage, Frontiers in Aging. Independent RCT, n=114 older adults, 2 weeks at 3 doses: missed its primary endpoint, no rise in glutathione redox ratio overall; only a high-oxidative-stress subset benefited. The key independent non-replication.
- Kumar P et al. 2022 - GlyNAC (Glycine and N-Acetylcysteine) Supplementation in Mice Increases Length of Life by Correcting Glutathione Deficiency, Oxidative Stress, Mitochondrial Dysfunction, Abnormalities in Mitophagy and Nutrient Sensing, and Genomic Damage, Nutrients. Aging-mouse study: GlyNAC corrected glutathione deficiency and multiple aging-hallmark defects and extended lifespan by 24 percent. Preclinical support for the human program.
- Sekhar RV et al. 2011 - Glutathione Synthesis Is Diminished in Patients With Uncontrolled Diabetes and Restored by Dietary Supplementation With Cysteine and Glycine, Diabetes Care. Diabetes patients plus controls: cysteine and glycine restored deficient glutathione synthesis and lowered oxidative stress despite persistent hyperglycemia. Early precursor evidence in a metabolic population.
- Prescott LF et al. 1977 - Treatment of paracetamol poisoning with N-acetylcysteine, The Lancet. Landmark trial establishing N-acetylcysteine, GlyNAC's cysteine donor, as the antidote that restores hepatic glutathione in acetaminophen overdose. Validates the precursor pathway and NAC's safety record.
- Richie JP Jr et al. 2015 - Randomized controlled trial of oral glutathione supplementation on body stores of glutathione, European Journal of Nutrition. 6-month RCT, n=54: oral glutathione raised stores 30 to 35 percent, a smaller gain than the precursor route produced, supporting the precursor-over-direct argument.
- FDA - Questions and Answers on Dietary Supplements. Regulatory context: glycine and N-acetylcysteine are sold as OTC dietary supplements; FDA does not pre-approve dietary supplement safety or effectiveness before marketing.
What does the evidence say about GlyNAC (Glycine + N-Acetylcysteine)?
Evidence on this intervention is summarized across three complementary streams: contemporary clinical research, pre-RCT-era pharmacology and observational use, and the traditional medical systems that documented it first. Convergence across streams signals higher confidence; divergence is surfaced honestly.
Modern Clinical Research
Confidence: Medium
Citations: Sekhar 2011, Kumar 2021, Kumar 2023, Sekhar 2022, Lizzo 2022, Richie 2015
Holistic Evidence for GlyNAC (Glycine + N-Acetylcysteine)
The mechanistic and clinical evidence agree that the precursor route reliably raises glutathione, while the open question is whether the single-lab magnitude of the functional and metabolic benefits will hold up in larger, independent trials.
What to Track If You Try This
These are the data points that matter most while running a 30-day Experiment with this intervention.
How to read this section
- Pre
- Test or score before starting the protocol. Anchors a baseline.
- During
- Track while running the protocol so you can see if anything is changing.
- Post
- Re-test after a full cycle to confirm the change held.
- Up
- The marker should rise. For most positive outcomes, that is a good sign.
- Down
- The marker should fall. For most positive outcomes, that is a good sign.
- Stable
- The marker should hold steady. Big swings in either direction are a yellow flag.
- Watch
- Direction depends on dose, timing, and your baseline. Pay close attention to the trend.
- N/A
- No expected direction. The entry is there to anchor a baseline reading.
- Primary
- The Pulse dimension most likely to shift. Track this first.
- Secondary
- Also relevant, but a smaller or less consistent shift. Track if Primary is unclear.
Bloodwork to Order
Open These Markers In Your Dashboard
- HbA1c Pre | Expected Watch Post | Expected Down
- hs-CRP During | Expected Down
- GGT During | Expected Watch
Pulse Dimensions to Watch
- Energy During | Expected Up | Secondary
- Body During | Expected Up | Primary
Subjective Signals (Daily Voice Card)
- Daily energy and post-exertion recovery Scale 1-5 | During | Expected Up
- Grip and lower-body strength in daily tasks Scale 1-5 | During | Expected Up
Red Flags: Stop and Consult
- New or worsening asthma wheeze after NAC: rare bronchospasm has been reported; stop and consult a clinician.
- Persistent nausea, vomiting, or GI distress at high NAC doses: lower the dose or take with food.
Other interventions for Mitochondrial
See all ratings →📊 How BioHarmony scoring works
BioHarmony translates a weighted expected-value calculation into a reader-facing 0–10 score. Tier bands: Skip 0–2.9, Caution 3.0–4.4, Neutral 4.5–5.7, Worth Trying 5.8–6.9, Strong Recommend 7.0–8.7, Top-tier 8.8–10.0.
Harm-type downsides (safety risk, side effects, reversibility, dependency) carry a 1.4× precautionary multiplier. Harm weighs more than benefit. Opportunity-type downsides (financial cost, time/effort, opportunity cost) are subtracted at face value.
Use case subratings are independent assessments of how well the intervention addresses specific health goals. They are not components of the overall score. Each subrating reflects the scorer's judgment based on use-case-specific evidence, safety, and effect sizes.
Every dimension is evaluated on a 1–5 scale, and the baseline (1) is subtracted before weighting. A perfect intervention with zero downsides contributes zero penalty rather than a residual floor, so top-tier scores are actually reachable.
EV = Upside − Downside
EV = 2.100 − 0.714 = 1.386
Formula v2.0 maps EV = 0 to score 5.0. Above neutral, EV = +4.00 reaches 10.0; below neutral, EV = −5.36 reaches 0.0. Both sides use the full 5-point half-scale.
Score = 5 + (1.386 / 4.00) × 5 = 6.7 / 10
